Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results - Sorbonne Université Access content directly
Journal Articles PLoS ONE Year : 2017

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results

Jenny Link
  • Function : Author
Ryan Ramanujam
  • Function : Author
Michael Auer
  • Function : Author
Malin Ryner
  • Function : Author
Delphine Bachelet
  • Function : Author
Cyprien Mbogning
  • Function : Author
Clemens Warnke
  • Function : Author
Dorothea Buck
  • Function : Author
Poul Erik Hyldgaard Jensen
  • Function : Author
Claudia Sievers
  • Function : Author
Kathleen Ingenhoven
  • Function : Author
Nicolas Fissolo
  • Function : Author
Raija Lindberg
  • Function : Author
Verena Grummel
  • Function : Author
Naoimh Donnellan
  • Function : Author
Manuel Comabella
  • Function : Author
Xavier Montalban
  • Function : Author
Bernd Kieseier
  • Function : Author
Per Soelberg Sørensen
  • Function : Author
Hans-Peter Hartung
  • Function : Author
Tobias Derfuss
  • Function : Author
Andy Lawton
  • Function : Author
Dan Sikkema
  • Function : Author
Marc Pallardy
Bernhard Hemmer
  • Function : Author
Florian Deisenhammer
  • Function : Author
Philippe Broët
  • Function : Author
Pierre Dönnes
  • Function : Author
Julie Davidson
  • Function : Author
Anna Fogdell-Hahn
  • Function : Author

Abstract

Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a wellintegrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (IFNβ) and natalizumab have been pooled and characterized through collaboration within a European consortium. The aim of this study was to report on the clinical practice of ADA testing in Europe, considering the number of ADA tests performed and type of ADA assays used, and to determine the frequency of ADA testing against the different drug preparations in different countries. A common database platform (tranSMART) for querying, analyzing and storing retrospective data of MS cohorts was set up to harmonize the data and compare results of ADA tests between different countries. Retrospective data from six countries (Sweden, Austria, Spain, Switzerland, Germany and Denmark) on 20,695 patients and on 42,555 samples were loaded into tranSMART including data points of age, gender, treatment, samples, and ADA results. The previously observed immunogenic difference among the four IFNβ preparations was confirmed in this
Fichier principal
Vignette du fichier
file.pdf (1.57 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-03978965 , version 1 (08-02-2023)

Identifiers

Cite

Jenny Link, Ryan Ramanujam, Michael Auer, Malin Ryner, Signe Hässler, et al.. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12 (2), pp.e0170395. ⟨10.1371/journal.pone.0170395⟩. ⟨hal-03978965⟩
5 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More